Biomarker for ovarian and endometrial cancer: hepcidin
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 31, 2009
Grant Date -
Mar 8, 2007
app pub date -
Mar 10, 2006
filing date -
Mar 11, 2005
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully